Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $160
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.
